How to Facilitate Seamless Translation from Basic Concepts to New Heart Failure Drugs. A Scientific Statement of the Heart Failure Association of the ESC

A rift has opened and is widening between basic research (bench) and clinical research and patients (bed) who need their new treatments, diagnostics and preventive strategies. This problem involving the 'translation' of basic scientific findings into clinical applications and potential treatments or biomarkers for a condition like heart failure is widely recognized both in academia and industry. Despite the attempts that have been made by both sides to improve this situation, the high attrition rates of drug development and the problem with reproducibility and translatability of preclinical findings to human applications still persist. As a result, the return on investment of basic research has been limited in terms of clinical impact. In this scientific statement we describe and discuss various issues with relevance to this theme and try to dissect how to move our field towards the development of more effective heart failure drugs. We zoom in on facilitating the process of heart failure drug development, the unnecessary gaps ('valley of death') between the critical steps in heart failure drug development, validation and de-validation of new concepts as early as possible ('rigorous translation'). We describe forums on how to stimulate cross-talk and interaction between clinician-scientists, basic heart failure researchers, biotech and industry, and how to enable them to speak the same language, and lessons learned from successes outside the heart failure field.

Authors

Institutions

Publication Details

Journal
European Journal of Heart Failure
Published
2025-06-18
DOI
https://doi.org/10.1002/ejhf.3709
Citations
5
Primary Topic
Heart Failure Treatment and Management
Type
article
Field-Weighted Citation Impact
6.94

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

How to Facilitate Seamless Translation from Basic Concepts to New Heart Failure Drugs. A Scientific Statement of the Heart Failure Association of the ESC

Arantxa González, Giuseppe Rosano, Bert Klebl, Rusty L. Montgomery et al.
5 citations
European Journal of Heart Failure
Heart Failure Treatment and Management
6.94
article

How to Facilitate Seamless Translation from Basic Concepts to New Heart Failure Drugs. A Scientific Statement of the Heart Failure Association of the ESC

Arantxa González, Giuseppe Rosano, Bert Klebl, Rusty L. Montgomery, Frank Thomas Ruschitzka, Antoni Bayes-genis A, Linda van Laake, Thomas Thum, Sophie Van Linthout, Peter P. Rainer, Rudolf A. de Boer, Jean‐Luc Balligand, Piero Pollesello, Rick Gorczynski, Giuseppe Vergaro, Ida G. Lunde, Christoph Maack, Andrew J.S. Coats, Gabriele G. Schiattarella, Marco Metra, Carlo G. Tocchetti, Alexander Richard Lyon, Milena Bellin, Inês Falcão‐Pires, Oliver Josef Müller, Johannes Backs, Timothy A. McKinsey, Petar Seferović, Jean‐Sébastien Hulot, Emilio Hirsch, Glenn Begley, Peter van der Meer, Ildiko Bock Marquette
article en
5 citations

Abstract

A rift has opened and is widening between basic research (bench) and clinical research and patients (bed) who need their new treatments, diagnostics and preventive strategies. This problem involving the 'translation' of basic scientific findings into clinical applications and potential treatments or biomarkers for a condition like heart failure is widely recognized both in academia and industry. Despite the attempts that have been made by both sides to improve this situation, the high attrition rates of drug development and the problem with reproducibility and translatability of preclinical findings to human applications still persist. As a result, the return on investment of basic research has been limited in terms of clinical impact. In this scientific statement we describe and discuss various issues with relevance to this theme and try to dissect how to move our field towards the development of more effective heart failure drugs. We zoom in on facilitating the process of heart failure drug development, the unnecessary gaps ('valley of death') between the critical steps in heart failure drug development, validation and de-validation of new concepts as early as possible ('rigorous translation'). We describe forums on how to stimulate cross-talk and interaction between clinician-scientists, basic heart failure researchers, biotech and industry, and how to enable them to speak the same language, and lessons learned from successes outside the heart failure field.

European Journal of Heart FailureVol. 27(8)
Universitat Autònoma de Barcelona (ES), Oslo University Hospital (NO), Cliniques Universitaires Saint-Luc (BE), University Medical Center Groningen (NL), University of Padua (IT), Inserm (FR), Scuola Superiore Sant'Anna (IT), University of Groningen (NL), Universidade do Porto (PT), Parthenope University of Naples (IT), University of Oslo (NO), Università degli studi di Cassino e del Lazio Meridionale (IT), Medical University of Graz (AT), University of Zurich (CH), Max Delbrück Center (DE), Heidelberg University (DE), Leiden University Medical Center (NL), The Heart Research Institute (AU), Erasmus MC (NL), University Hospital Heidelberg (DE), San Raffaele University of Rome (IT), University Medical Center Utrecht (NL), Medizinische Hochschule Hannover (DE), University of Belgrade (RS), Veneto Institute of Molecular Medicine (IT), Centro de Investigación en Red en Enfermedades Cardiovasculares (ES), Royal Brompton Hospital (GB), Assistance Publique – Hôpitaux de Paris (FR), Grade Medical (Czechia) (CZ), University Hospital of Zurich (CH), Hôpital Européen Georges-Pompidou (FR), Surgical Specialties (Canada) (CA), Hôpital Européen (FR), Fraunhofer Institute for Toxicology and Experimental Medicine (DE), University Hospital Schleswig-Holstein (DE), Centro de Investigación Biomédica en Red (ES), BioTechMed-Graz (AT), Federico II University Hospital (IT), Orion Corporation (Finland) (FI), Lead Discovery Center (Germany) (DE), Universitätsklinikum Würzburg (DE), German Centre for Cardiovascular Research (DE), Paris Cardiovascular Research Center (FR), Clinica Universidad de Navarra (ES), Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (ES), Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE), Gilead Sciences (United States) (US), Erasmus MC Cancer Institute (NL), PDL BioPharma (United States) (US), Hospital Universitari Germans Trias i Pujol (ES), Fondazione Toscana Gabriele Monasterio (IT), Ribon Therapeutics (United States) (US), Imperial College London (GB), Fraunhofer-Gesellschaft (DE), University of Colorado Anschutz Medical Campus (US), University of Turin (IT), Charité - Universitätsmedizin Berlin (DE), University of Pecs (HU), University of Brescia (IT), Orion Corporation (United Kingdom) (GB), Heidelberg University (US), University of Lübeck (DE), UCLouvain (BE)
Deutsche Forschungsgemeinschaft, Ministero della Salute, Deutsche Krebshilfe, Instituto de Salud Carlos III
Openalex Percentile: Top 3%
Heart Failure Treatment and Management
6.94
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.